OncoMatch/Clinical Trials/NCT06959615
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Is NCT06959615 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including JAB-23E73 and JAB-23E73 for advanced solid tumor.
Treatment: JAB-23E73 · JAB-23E73 — This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid tumors harboring KRAS mutations or amplification. The study consists of 2 phases: Phase 1 Dose Escalation and Phase IIa Dose Expansion.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: KRAS gene mutation
evidence of KRAS gene alteration (including gene mutation and wild type amplification)
Required: KRAS amplification
evidence of KRAS gene alteration (including gene mutation and wild type amplification)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: RAS targeting agent
Previous treatment with rat sarcoma (RAS) targeting agents
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Impaired cardiovascular function or clinically significant cardiac disease; QTcF >470 msec excluded
Adequate organ function. Impaired cardiovascular function or clinically significant cardiac disease. Mean QT interval corrected using Fridericia's formula (QTcF) >470 msec.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify